Mikael Dolsten, Pfizer’s former research chief, has pulled his candidacy for a seat on Novo Nordisk’s board, citing personal reasons, the Danish drugmaker said. The move could alter investor sentiment for tokenized pharma exposure and governance-focused crypto products.